MSD bets big on flu antivirals with $9.2bn buyout of Cidara
MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming patent expiry.
Therapy Area
Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim
General Proximity and Daiichi Sankyo link on oncology
Sandoz CEO forecasts a Q1 or Q2 market entry for semaglutide biosimilars in Canada
Modulight secures $12m to shine precise light on neurological diseases
FDA calls for black box warning to be removed from HRT products
AHA 2025: semaglutide 2.4mg lowers cardiovascular risk in SCORE-HF Study
Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer
